Immunotherapy最新文献

A plain language summary of a review about omalizumab for people with chronic spontaneous urticaria.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-07 DOI: 10.1080/1750743X.2025.2484921

Thomas B Casale, Ana Maria Gimenez-Arnau, Jonathan A Bernstein, Michael Holden, Torsten Zuberbier, Marcus Maurer

引用次数: 0

Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-04 DOI: 10.1080/1750743X.2025.2485012

Courtney H Coschi, Keyue Ding, Justin Tong, Dongsheng Tu, Christopher O'Callaghan, Natasha B Leighl, Francisco Vera-Badillo, Rosalyn A Juergens, Desiree Hao, Lesley Seymour, Daniel J Renouf, Eric Chen, Pierre-Olivier Gaudreau, Andrea S Fung

{"title":"Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data.","authors":"Courtney H Coschi, Keyue Ding, Justin Tong, Dongsheng Tu, Christopher O'Callaghan, Natasha B Leighl, Francisco Vera-Badillo, Rosalyn A Juergens, Desiree Hao, Lesley Seymour, Daniel J Renouf, Eric Chen, Pierre-Olivier Gaudreau, Andrea S Fung","doi":"10.1080/1750743X.2025.2485012","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2485012","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) benefit patients across various tumor types. ICIs block cancer and T-cell interactions whereas cannabinoids may inhibit T-cell activation, reducing lysis of tumor cells. Interactions between cannabinoid use and dual ICI treatment remain unknown.Methods: Individual patient data from 4 Canadian Cancer Trials Group (CCTG) trials of patients treated with dual ICI ± chemotherapy (n = 684) were pooled. Cochran - Mantel - Haenszel and log-rank tests (stratified by trial/treatment arms) correlated cannabinoid use with clinicopathologic characteristics, Best Overall Response (BOR)/iBOR per RECIST 1.1/iRECIST, Progression-Free Survival (PFS)/iPFS, Overall Survival (OS) and immune-related adverse events (irAEs).Results: Sixty-five (9.5%) patients took cannabinoids at any time on trial, 32 (4.7%) of which were using cannabinoids at baseline. By multivariate analysis, cannabinoid use at baseline was significantly associated with improved iPFS (0.05), but not iBOR (p = 0.15), PFS (p = 0.12), OS (p = 0.35) or incidence of grade 1/2 or 3/4 irAEs (p = 0.96 and 0.65 respectively). Results were not significantly different with cannabinoid use at any time on trial.Conclusion: Improved iPFS with cannabinoid use in patients treated with durvalumab plus tremelimumab ± chemotherapy did not translate into OS benefits. This study supports the safe use of cannabinoids in the context of combination ICI therapy.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":2.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143784464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors. 接受免疫检查点抑制剂治疗的肺癌患者发生免疫相关不良事件的真实世界数据。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-04 DOI: 10.1080/1750743X.2025.2488728

Xiao Hu, Angie Mae Rodday, Anastasia Gurinovich, Stacey Pan, Yana V Salei, Jeffrey H Lin, Margaret M Byrne, Yu Cao, Lori Pai, Susan K Parsons

{"title":"Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors.","authors":"Xiao Hu, Angie Mae Rodday, Anastasia Gurinovich, Stacey Pan, Yana V Salei, Jeffrey H Lin, Margaret M Byrne, Yu Cao, Lori Pai, Susan K Parsons","doi":"10.1080/1750743X.2025.2488728","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2488728","url":null,"abstract":"Background: Immune-checkpoint inhibitors (ICIs) have revolutionized lung cancer (LC) treatment; however, immune-related adverse effects (irAEs) may occur. The risk factors of irAEs and the impact of irAEs on patient outcomes in LC remain uncertain.Materials and methods: irAEs within 12 months of ICI initiation in LC patients who initiated ICIs 2018-2021 were identified. Cause-specific Cox regression was used to assess risk factors for irAEs with the competing risk of death; a subset analysis was done among non-small cell lung cancer (NSCLC) group. Multivariable Cox regressions were used to evaluate the impact of irAEs on progression-free survival (PFS) and overall survival (OS).Results: Of 125 patients, 50 irAEs occurred in 39 patients. Small cell lung cancer (SCLC) histology was associated with a higher risk of irAEs (Hazard ratio (HR) = 2.73, 95% CI [1.17, 6.35], p = 0.020) than NSCLC. In NSCLC subset, programmed death-ligand 1 (PDL1) positivity (HR = 2.68, 95% CI [1.10. 6.53], p = 0.030) was identified as a risk factor. irAEs were not significantly associated with PFS (HR = 0.69, p = 0.204) or OS (HR = 0.72, p = 0.353).Conclusion: SCLC histology and PDL1 positivity were associated with irAEs, and the occurrence of irAEs showed no impact on survival in LC patients. Future studies are required to validate the findings.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case report.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-04-02 DOI: 10.1080/1750743X.2025.2488609

Bahadır Köylü, Cevat İlteriş Kıkılı, Öner Dikensoy, Fatih Selçukbiricik

{"title":"Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case report.","authors":"Bahadır Köylü, Cevat İlteriş Kıkılı, Öner Dikensoy, Fatih Selçukbiricik","doi":"10.1080/1750743X.2025.2488609","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2488609","url":null,"abstract":"Immune-related adverse events typically occur during the early phases of immune checkpoint inhibitor therapy. However, late-onset immune-related adverse events can still arise long after the immune checkpoint inhibitor therapy has ended. Immune checkpoint inhibitor-related pneumonitis warrants special attention for risk assessment and early detection due to its potential for serious outcomes, including hospitalization and death. Despite its rarity, late-onset immune checkpoint inhibitor-related pneumonitis should be considered in the differential diagnosis for dyspnea in patients with a history of immune checkpoint inhibitor therapy to prevent morbidity and mortality. In this case report, we present a case of an 84-year-old female patient suffering from locally advanced triple-negative breast cancer and late-onset immune checkpoint inhibitor-related pneumonitis requiring hospitalization 104 days after the last cycle of pembrolizumab. Following successful treatment of late-onset immune checkpoint inhibitor-related pneumonitis with corticosteroids, a recurrence of immune checkpoint inhibitor-related pneumonitis occurred a month later. Corticosteroid therapy was reinitiated, gradually tapered after radiological improvement, and eventually discontinued. The patient remains in remission from breast cancer. For patients with a history of immune checkpoint inhibitor therapy, medical vigilance, accurate diagnosis, and timely management of late-onset immune checkpoint inhibitor-related pneumonitis are crucial.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-4"},"PeriodicalIF":2.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the role of immune checkpoint inhibitors in solitary fibrous tumors.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-31 DOI: 10.1080/1750743X.2025.2485670

Tarek Assi, Tania Moussa, Axel Le Cesne

引用次数: 0

Benralizumab for the treatment of chronic spontaneous urticaria: a plain language summary of the ARROYO study. 本拉珠单抗治疗慢性自发性荨麻疹：ARROYO 研究的简明摘要。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-30 DOI: 10.1080/1750743X.2025.2480052

Sabine Altrichter, Ana Maria Giménez-Arnau, Jonathan A Bernstein, Martin Metz, Maria Bergquist, Laura Brooks, Calvin N Ho, Priya Jain, Pradeep B Lukka, Eva Rodriguez-Suárez, Claire Walton, Lila Bahadori

引用次数: 0

Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-28 DOI: 10.1080/1750743X.2025.2482510

Martina Catalano, Giulia Venturi, Alessia Salfi, Francesco Bloise, Federico Paolieri, Luca Galli, Michele Sisani, Laura Doni, Giandomenico Roviello

{"title":"Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients.","authors":"Martina Catalano, Giulia Venturi, Alessia Salfi, Francesco Bloise, Federico Paolieri, Luca Galli, Michele Sisani, Laura Doni, Giandomenico Roviello","doi":"10.1080/1750743X.2025.2482510","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2482510","url":null,"abstract":"Background: Immune (IO)-combination therapies have revolutionized the treatment of advanced renal cell carcinoma (aRCC) but are more frequently associated with adverse events (AEs) compared to tyrosine kinase inhibitors (TKI) alone. This retrospective study aimed to evaluate the incidence and prognostic significance of AEs in patients receiving combination therapies.Methods: We included patients treated with nivolumab/ipilimumab (NI), nivolumab/cabozantinib (NC), or pembrolizumab/axitinib (PA) at four Italian oncology centers between November 2023 and June 2024. The impact of AEs on progression-free survival (PFS), overall survival (OS), overall response, and disease control rate were analyzed using descriptive statistics, Kaplan-Meier method, and Cox regression.Results: AEs occurred in 78.8% of NI, 87.9% of NC, and 92.3% of PA patients. Grade 3-4 AEs were more common in IO-TKI vs. IO-IO combinations (32.9% vs. 15.1%, p = 0.05). Pruritus and pulmonary events were more frequent with IO-IO, while hypertension and mucositis were more common with IO-TKI. High-grade AEs did not impact PFS or OS, but TKI reduction due to AEs was associated with longer OS (p < 0.01). Steroid use also improved OS (p = 0.04).Conclusion: AEs are common in ICI-based therapies for RCC. While they do not negatively affect survival, their management, especially through dose reductions or steroids, may improve outcomes.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.7,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-25 DOI: 10.1080/1750743X.2025.2483656

Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, Oronzo Brunetti, Raffaella Massafra, Veronica Mollica, Francesco Massari, Matteo Santoni

{"title":"Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis.","authors":"Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, Oronzo Brunetti, Raffaella Massafra, Veronica Mollica, Francesco Massari, Matteo Santoni","doi":"10.1080/1750743X.2025.2483656","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2483656","url":null,"abstract":"Background: The MOUSEION-010 Meta-Analysis assessed the association between nutritional status and clinical outcomes such as Progression Free Survival (PFS) and Overall Survival (OS) among cancer patients treated with immune checkpoint inhibitors (ICIs).Methods: Nutritional status was assessed based on the Prognostic Nutrition Index (PNI), Geriatric Nutritional Risk Index (GNRI) and Controlling Nutritional Status (CONUT) indexes. Databases consulted were: Embase, PubMed, Scopus and Web of Science.Results: PNI and GNRI indexes did not show a significant association with both PFS and OS, while CONUT index displayed a significant difference in PFS between the two groups, in favor of the control group (Z = 4.04; p < 0.01) also without any publication bias (β= -1.27; 95% CI = [-2.13; -0.42]; p = 0.10]). The same trend was recorded in OS, too (Z = 4.24; p < 0.01). However, publication bias was present (β = 1.89; 95% CI = [1.26; 2.54]; p = 0.028]) and the numerosity of the studies did not reveal the sufficient statistical power to obtain reliable results.Conclusion: Malnutrition could negatively impact cancer patients, especially in advanced phases. Our findings could be associated with the reduction of physical ability and daily activity performance, lower compliance with treatment protocols, and shorter survival outcomes.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is it time to revisit the significance of PD-L1 expression in assisting our treatment decisions?

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-21 DOI: 10.1080/1750743X.2025.2483152

Georgios I Papageorgiou, Nikolaos Skouteris, Maria Grenzelia, Emmanouil Maragkoudakis, Kleopatra Eleftheriou

引用次数: 0

Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma.

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-03-18 DOI: 10.1080/1750743X.2025.2478808

Shravan Leonard-Murali, Udai S Kammula

{"title":"Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma.","authors":"Shravan Leonard-Murali, Udai S Kammula","doi":"10.1080/1750743X.2025.2478808","DOIUrl":"10.1080/1750743X.2025.2478808","url":null,"abstract":"Adoptive transfer of tumor infiltrating lymphocytes (TIL-ACT) is a personalized cancer therapy that harnesses the anti-tumor activity of tumor resident T cells through ex vivo activation and expansion. This therapy involves the infusion of a single dose of ex vivo expanded TIL together with high dose IL-2 following a preparative lymphodepleting chemotherapy. The United States Food and Drug Administration approved lifileucel in 2024 as the first autologous TIL product for patients with advanced cutaneous melanoma (CM), adding to the list of approved immunotherapies for this highly immunogenic cancer. However, the role for TIL-ACT in other solid tumors is unclear, especially for poorly immunogenic cancers with low tumor mutational burden. In this review, we describe the historical development of TIL-ACT, summarize the clinical results in advanced CM, and describe the novel application of TIL-ACT to metastatic uveal melanoma (UM), a prototypic immunotherapy-resistant solid tumor. We will highlight key biologic differences between CM and UM, their consequential influence on the manufacturing of UM-specific TIL products, and the development of novel biomarkers for precision TIL-ACT for metastatic UM.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0